Fourth Annual
Cancer Biologics
Approaches Changing the Treatment of Cancer
Day 1 | Day 2 | Day 3
Friday, February 15
8:00 am Morning Coffee
8:30 Chairperson's Remarks
Ivan D. Horak, M.D., F.A.C.P., CSO/CMO, R&D, Symphogen A/S
8:35 Improving Potency & Manufacturability of Bi-Specific Antibodies
Jason Baum, Ph.D., Principal Scientist, Research, Merrimack Pharmaceuticals, Inc.
Here we describe an optimization approach for multi-specific molecules targeting growth factor receptor signaling pathways that has been successfully applied to the design of MM-141, a stable high affinity bispecific antibody targeting IGF-1R and ErbB3.
9:05 Multi-Targeting Approaches in Oncology and Angiogenesis by Multi-Specific Darpins
Ulrike Fiedler, Ph.D., Principle Scientist, Disease Biology, Molecular Partners AG
This platform enables novel therapeutic concepts in which efficacy, PK, and mechanism of action are tailored to address unmet medical needs. We will highlight different pre-clinical programs.
9:35 BiTE® Antibodies for Cancer Therapy
Roman Kischel, M.D., Principal Scientist, BiTE Technology, Amgen Research (Munich) GmbH
10:05 Ang-2-VEGF Crossmab, a Novel Bi-specific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Function
Hubert Kettenberger, Ph.D., Principal Scientist, Pharma Research and Early Development (pRED), Roche Diagnostics GmbH
CrossMabs represent a new class of bispecific, IgG-like antibodies which can be expressed in a single, stably transfected CHO cell line. A CrossMab against the angiogenesis factors VEGF-A and Ang-2, which has recently entered clinical trials, will be presented.
10:35 Coffee Break
11:00 Targeting Multiple Oncology Sites with Multi-Specific Antibody-Like Molecules
Peter Kiener, Ph.D., President & CEO, Zyngenia, Inc.
The Zybody platform generates multi-specific antibodies with 2-5 specificities that can simultaneously engage multiple targets. This can give rise to "better than additive" responses to modulation of cell growth and signaling receptors and internalization. We will discuss some examples.
11:30 Pre-Clinical Advances with a Fully Human Bispecific Antibody Platform
Eric Smith, Ph.D., Associate Director, Bispecific Antibodies, Regeneron Pharmaceuticals, Inc.
Using mouse genetic engineering platforms at Regeneron (Velocigene, VelocImmune) a novel platform technology has been established to generate fully human bi-specific antibodies. This presentation will describe recent pre-clinical results in in vitro and in vivo model systems.
12:00 pm Employing the Bispecific RECRUIT TandAb Platform
Uwe Reusche, Ph.D., Head, Bioassay Group, R&D, Affimed Therapeutics AG
This technology comprises CD3 RECRUIT and CD16 RECRUIT modules for respective T and NK cell recruitment and killing of cancer cells. We will report on safety and efficacy, and activity in the clinic.
12:30 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own
1:45 Chairperson's Remarks
Ulrike Fiedler, Ph.D., Principle Scientist, Disease Biology, Molecular Partners AG
1:50 Combination Strategies to Enhance Anti-Tumor ADCC
Holbrook Kohrt, M.D., Ph.D., Assistant Professor, Oncology, University of Stanford
Here I discuss strategies that increase total target–monoclonal antibody–effector binding, strategies that trigger effector cell 'activating' signals, and strategies that block effector cell 'inhibitory' signals.
2:20 Observations with the ADC Trastuzumab Emtansine (T-DM1) Alone and in Combination
Steve Olsen, M.D., Ph.D., Global Development Team Leader, Trastuzumab Emtansine Product Development-Oncology, Genentech, Inc.
T-DM1 has demonstrated promising safety and efficacy as single-agent therapy for HER2-positive metastatic breast cancer. Combining T-DM1 with other HER2-directed therapy and/or chemotherapy has the potential to improve clinical efficacy. Pre-clinical and emerging clinical data will be discussed.
2:50 Novel Strategy to Target Tyrosine Kinase Receptors: From Bench to Clinic
Ivan D. Horak, M.D., F.A.C.P., CSO/CMO, R&D, Symphogen A/S
3:20 Close of Conference
Day 1 | Day 2 | Day 3